Thomas Bourgeron
Professor
University Paris Diderot
From this contributor
Expliquer la résilience à l’autisme peut faire naître de nouvelles thérapies
Explaining ‘resilience’ in autism may seed new therapies
Some individuals who have autism mutations show no signs of the condition; understanding why may lead to treatments.
Explaining ‘resilience’ in autism may seed new therapies
Questions for Thomas Bourgeron: In search of ‘second hits’
Taking a close look at people who have a mutation in a known autism gene may reveal why these people often have vastly different characteristics.
Questions for Thomas Bourgeron: In search of ‘second hits’
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.